GRAIL, Inc. (NASDAQ:GRAL) Receives $107.83 Consensus Price Target from Brokerages

GRAIL, Inc. (NASDAQ:GRAL) has earned a consensus rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $98.50.

A number of equities research analysts have issued reports on GRAL shares. Morgan Stanley upped their target price on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Guggenheim boosted their target price on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. TD Cowen initiated coverage on GRAIL in a research note on Thursday. They set a “hold” rating and a $114.00 target price for the company. Canaccord Genuity Group lowered their price objective on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. bought a new stake in GRAIL in the 4th quarter valued at $7,414,000. Invesco Ltd. boosted its position in shares of GRAIL by 1.0% during the 4th quarter. Invesco Ltd. now owns 137,967 shares of the company’s stock valued at $11,809,000 after acquiring an additional 1,422 shares in the last quarter. Corient Private Wealth LLC increased its stake in GRAIL by 59.7% in the fourth quarter. Corient Private Wealth LLC now owns 9,233 shares of the company’s stock valued at $790,000 after acquiring an additional 3,450 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in GRAIL in the fourth quarter worth about $303,000. Finally, Regal Partners Ltd acquired a new position in GRAIL in the fourth quarter worth about $342,000.

GRAIL Stock Down 50.5%

GRAL stock opened at $50.21 on Thursday. The firm has a 50 day moving average of $96.61 and a two-hundred day moving average of $76.23. GRAIL has a 12 month low of $20.44 and a 12 month high of $118.84. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -4.49 and a beta of 4.52.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.33) by $0.89. The business had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. On average, research analysts expect that GRAIL will post -15.15 EPS for the current fiscal year.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Company reported beats on Q4 revenue and EPS, growth in U.S. Galleri sales, stated cash runway into 2030 and completed a PMA submission to the FDA — fundamental items that support longer‑term commercialization potential. GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Topline trial data also showed a substantial reduction in stage IV diagnoses and increased stage I–II detection for some cancers — outcomes investors may view as clinically meaningful even though the primary endpoint was not met. These secondary signals could support follow‑up analyses or regulatory discussions. Landmark NHS‑Galleri Trial Demonstrates …
• Positive Sentiment: At least one research house maintained a favorable view (Outperform) after the news, indicating some analysts believe the selloff may be overdone and the company retains upside if follow‑up data or regulatory feedback is constructive. GRAIL (NASDAQ:GRAL) Earns Outperform Rating from Analysts at Robert W. Baird
• Neutral Sentiment: Several headlines and commentaries are assessing whether the market reaction is an overreaction and noting that more detailed follow‑up analyses could change interpretation — keep an eye on full data releases and management commentary. Why is GRAL stock down today? Analysts lower targets …
• Neutral Sentiment: Reported short‑interest data in the feed appears unreliable/zeroed out (likely a data error) and should not be used to infer shareholder positioning or days‑to‑cover at this time. Market data summary for GRAL
• Negative Sentiment: Primary endpoint for the 3‑year NHS‑Galleri randomized trial was not met (no statistically significant combined reduction in Stage III–IV diagnoses), which directly undercut the test’s flagship clinical claim and triggered the steep share decline. Grail shares plunge after major cancer screening trial misses main goal
• Negative Sentiment: Multiple news outlets and analysts pushed negative headlines after the trial miss, amplifying selling pressure and volatility despite the company’s otherwise positive quarterly metrics. Here’s Why Grail Stock Crashed 50% Today
• Negative Sentiment: Two law firms have opened securities‑litigation investigations into GRAIL, increasing legal risk and potential distraction for management; this typically weighs on sentiment and can prolong downside pressure. GRAL ALERT: Investigation Launched into GRAIL, Inc.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.